Sandler E D, Parisi M T, Hattner R S
Department of Radiology, UCSF, California.
J Nucl Med. 1991 Sep;32(9):1782-4.
There have been several reports of etidronate disodium (EHDP) interference upon the biodistribution of 99mTc-methylene diphosphonate (MDP). With the increasing use of etidronate for the treatment of Paget's disease, hypercalcemia, and osteoporosis, nuclear physicians can expect to encounter increasing numbers of cases in which EHDP-induced artifacts impair the diagnostic utility of bone scans. The temporal duration of this effect is unknown yet obviously important. We report serial bone scintigraphy in a patient who received a single dose of EHDP for hypercalcemia. Normal biodistribution of 99mTc-MDP was noted at 15 days, suggesting that 2 wk are sufficient before performing a bone scan after a single intravenous dose of etidronate.
已有多篇关于依替膦酸二钠（EHDP）对99m锝-亚甲基二膦酸盐（MDP）生物分布产生干扰的报道。随着依替膦酸在治疗佩吉特病、高钙血症和骨质疏松症方面的应用日益增加，核医学医师可能会遇到越来越多因EHDP引起的伪影影响骨扫描诊断效用的病例。这种影响的持续时间尚不清楚，但显然很重要。我们报告了一名因高钙血症接受单剂量EHDP治疗的患者的系列骨闪烁显像情况。在第15天时观察到99mTc-MDP的生物分布正常，这表明单次静脉注射依替膦酸后2周足以进行骨扫描。
